Mazowiecki Szpital Onkologiczny - szpital położony w Wieliszewie k/ Legionowa. Zgodnie z profilem szpital udostępnia różne metody leczenia nowotworów: chirurgiczne, radioterapie, chemioterapie, ambulatoryjną opiekę specjalistyczną, profilaktyczne programy zdrowotne. Placówka rozpoczęła działalność 4 stycznia 2010 r.

During the past decade, Mazowiecki Szpital Onkologiczny conducted 9 clinical trials. In the 10-year time frame, 9 clinical trials started and 4 clinical trials were completed, i.e. on average, 44.4% percent of trials that started reached the finish line to date. In the past 5 years, 3 clinical trials started and 4 clinical trials were completed. i.e. 133.3% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Mazowiecki Szpital Onkologiczny" #1 sponsor was "Basilea Pharmaceutica" with 1 trials, followed by "Bayer" with 1 trials sponsored, "BeiGene" with 1 trials sponsored, "EMD Serono Research & Development Institute, Inc." with 1 trials sponsored and "Hoffmann-La Roche" with 1 trials sponsored. Other sponsors include -1 different institutions and companies that sponsored additional 9 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Mazowiecki Szpital Onkologiczny" #1 collaborator was "Accelovance" with 1 trials as a collaborator, "Bioscience, S.A." with 1 trials as a collaborator, "Braster S.A." with 1 trials as a collaborator, "Merck KGaA, Darmstadt, Germany" with 1 trials as a collaborator and "Merck Sharp & Dohme LLC" with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 7 trials.

According to Clinical.Site data, the most researched conditions in "Mazowiecki Szpital Onkologiczny" are "Advanced or Inoperable Gastric Cancer" (1 trials), "Breast Cancer" (1 trials), "Cancer" (1 trials), "First Line Non-Small Cell Lung Cancer" (1 trials) and "HER-2 Positive Breast Cancer" (1 trials). Many other conditions were trialed in "Mazowiecki Szpital Onkologiczny" in a lesser frequency.

Most popular intervention types in "Mazowiecki Szpital Onkologiczny" are "Drug" (8 trials), "Biological" (2 trials), "Device" (1 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Carboplatin" (2 trials), "Cisplatin" (2 trials), "Placebo" (2 trials), "5-Fluorouracil" (1 trials) and "Atezolizumab" (1 trials). Other intervention names were less common.

The vast majority of trials in "Mazowiecki Szpital Onkologiczny" are 7 trials for "All" genders, 1 trials for "Female" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "Mazowiecki Szpital Onkologiczny". undefined are not yet recruiting, 1 are recruiting, 3 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 4 completed trials in Mazowiecki Szpital Onkologiczny, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Mazowiecki Szpital Onkologiczny, 1 "Phase 1" clinical trials were conducted, 3 "Phase 2" clinical trials and 5 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".